Filing Details
- Accession Number:
- 0001209191-20-002650
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2020-01-08 21:12:38
- Reporting Period:
- 2020-01-06
- Accepted Time:
- 2020-01-08 21:12:38
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
921299 | Fibrogen Inc | FGEN | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1775295 | Christine Chung | C/O Fibrogen, Inc. 409 Illinois St. San Francisco CA 94158 | Svp, China Operations | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2020-01-06 | 5,625 | $25.40 | 138,269 | No | 4 | M | Direct | |
Common Stock | Disposition | 2020-01-06 | 5,625 | $42.98 | 132,644 | No | 4 | S | Direct | |
Common Stock | Acquisiton | 2020-01-07 | 5,625 | $25.40 | 138,269 | No | 4 | M | Direct | |
Common Stock | Disposition | 2020-01-07 | 5,625 | $42.76 | 132,644 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Option (Right to Buy) | Disposition | 2020-01-06 | 5,625 | $0.00 | 5,625 | $25.40 |
Common Stock | Stock Option (Right to Buy) | Disposition | 2020-01-07 | 5,625 | $0.00 | 5,625 | $25.40 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
59,339 | 2027-03-08 | No | 4 | M | Direct | |
53,714 | 2027-03-08 | No | 4 | M | Direct |
Footnotes
- Shares sold pursuant to a 10b5-1 plan.
- The shares were sold at prices ranging from $42.555 to $43.36. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- The shares were sold at prices ranging from $42.49 to $43.07. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- Twenty-five percent of the shares subject to the option vested on March 1, 2018, and the remainder vested in equal amounts quarterly thereafter for the following three years.